Insider TradingJun 15, 2026, 07:02 AM
Tiziana Executive Chairman Increases Shareholding to 34.89%
AI Summary
Tiziana Life Sciences announced that its Executive Chairman and Founder, Mr. Gabriele Cerrone, through Panetta Partners Ltd, increased his holdings by purchasing 15,000 common shares at $1.11 per share. This acquisition brings his total holding to 44,772,230 common shares, representing 34.89% of the company's issued share capital. Tiziana continues to advance its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, which is currently being studied in an Expanded Access Program and a Phase 2a trial for non-active secondary progressive multiple sclerosis.
Key Highlights
- Executive Chairman Gabriele Cerrone purchased 15,000 common shares.
- Shares were acquired at $1.11 per share.
- Total holding increased to 44,772,230 common shares.
- This represents 34.89% of Tiziana's issued share capital.
- Intranasal foralumab is in an Expanded Access Program for 14 na-SPMS patients.
- Foralumab is also in a Phase 2a trial for non-active secondary progressive multiple sclerosis.
Price Impact
More from TLSA